| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2018005374 |
| Title |
Immunomodulator Compounds. |
| Abstract |
Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. |
| Applicant(s) |
Chemocentryx, Inc |
| Representative Drug(s) |
D08VDV |
Drug Info
|
IC50 < 100 nM |
Click to Show More |
[1] |
|
2
|
D0K7NC
|
Drug Info
|
IC50 < 100 nM
|
[1] |
| Patent ID |
WO2018051255 |
| Title |
Cyclic Substituted-1,3,4-Oxadiazole and Thiadiazole Compounds As Immunomodulators. |
| Abstract |
The present invention relates to cyclic substituted 1,3,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2. |
| Applicant(s) |
Aurigene Discovery Technologies Limited |
| Representative Drug(s) |
D0LM6D |
Drug Info
|
N.A. |
Click to Show More |
[1] |
|
2
|
D0P3EG
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2018051254 |
| Title |
Cyclic Substituted-1,2,4-Oxadiazole Compounds As Immunomodulators. |
| Abstract |
The present invention relates to cyclic substituted-1,2,4-oxadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signalling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2. |
| Applicant(s) |
Aurigene Discovery Technologies Limited |
| Representative Drug(s) |
D03PSA |
Drug Info
|
N.A. |
Click to Show More |
[1] |
|
2
|
D0MZ4V
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2016142835 |
| Title |
Therapeutic Cyclic Compounds As Immunomodulators. |
| Abstract |
The present invention relates to cyclic compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2. |
| Applicant(s) |
Aurigene Discovery Technologies Limited |
| Representative Drug(s) |
D00ZRO |
Drug Info
|
N.A. |
Click to Show More |
[1] |
|
2
|
D03XZT
|
Drug Info
|
N.A.
|
[1] |
|
3
|
D07PJR
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2016011160 |
| Title |
Compositions for Treating Cancer Using Pd-1 Axis Binding Antagonists and Mek Inhibitors. |
| Abstract |
The present invention describes combination treatment comprising a PD- 1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer. |
| Applicant(s) |
GENENTECH, INC. F. HOFFMAN-LA ROCHE AG |
| Patent ID |
WO2015200119 |
| Title |
Covalently Bonded Diabodies Having Immunoreactivity with Pd-1 and Lag-3, and Methods of Use Thereof. |
| Abstract |
The present invention is directed to bi-specific diabodies that comprise two or more polypeptide chains and which possess at least one Epitope-Binding Site that is immunospecific for an epitope of PD-1 and at least one Epitope-Binding Site that is immunospecific for an epitope of LAG-3 (i.e., a "PD-I x LAG-3 bi-specific diabody"). More preferably, the present invention is directed to bi-specific diabodies that comprise four polypeptide chains and which possess two Epitope-Binding Sites that are immunospecific for one (or two) epitope(s) of PD-1 and two Epitope-Binding Site that are immunospecific for one (or two) epitope(s) of LAG-3 (i.e., a "PD-1 x LAG-3 bi-specific, tetra-valent diabody"). |
| Applicant(s) |
Macrogenics, Inc |
| Patent ID |
WO2015155738 |
| Title |
Use of Gsk-3 Inhibitors or Activators Which Modulate Pd-1 or T-Bet Expression To Modulate T Cell Immunity. |
| Abstract |
The present application generally relates to the discovery that glycogen synthase kinase 3 (GSK-3) is an upstream signalling molecule that controls PD-1 transcription and Tbet expression by immune cells and in particular T-cells. Based on this discovery, and in view of the known immunosuppressive effect of PD-1 on immunity and the promoting effect of Tbet on T cell immunity, the present invention relates to the use of GSK-3 inhibitors to promote immunity, including cytotoxic T cell immunity in subjects in need thereof, especially subjects with chronic conditions wherein inhibiting PD-1 expression and/or blockade or Tbet upregulation is therapeutically desirable such as cancer and infectious conditions. Further, based on this discovery the present invention relates to the use of compounds which promote GSK-3 expression or activity to suppress immunity, especially aberrant T cell immunity in subjects in need thereof, e.g., subjects with chronic conditions wherein PD-1 upregulation or Tbet down regulation is therapeutically desirable such as allergic, autoimmune or inflammatory conditions. Also, screening methods for identifying immune agonists and antagonists, especially antibodies, are provided. |
| Applicant(s) |
Rudd, Christopher |
| Patent ID |
WO2015119944 |
| Title |
Combination of A Pd-1 Antagonist and An Ido1 Inhibitor for Treating Cancer. |
| Abstract |
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a selective inhibitor of indoleamine 2, 3-dioxygenase 1 (IDO1), and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1. |
| Applicant(s) |
Incyte Corporation |
| Patent ID |
WO2015119930 |
| Title |
Combination of A Pd-1 Antagonist and A Vegfr Inhibitor for Treating Cancer. |
| Abstract |
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-Ll. |
| Applicant(s) |
Pfizer Inc |
| Patent ID |
WO2015119923 |
| Title |
Combination of A Pd-1 Antagonist and A 4-Abb Agonist for Treating Cancer. |
| Abstract |
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a selective 4-1 BB agonist, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-Ll. |
| Applicant(s) |
Pfizer Inc |
| Patent ID |
WO2015112900 |
| Title |
Antibody Molecules To Pd-1 and Uses Thereof. |
| Abstract |
Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders. |
| Applicant(s) |
DANA-FARBER CANCER INSTITUTE, INC. NOVARTIS AG PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| Patent ID |
WO2015112800 |
| Title |
Human Antibodies To Pd-1. |
| Abstract |
The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death- 1 (PD-1 ) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T- cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder. |
| Applicant(s) |
Regeneron Pharmaceuticals, Inc |
| Patent ID |
WO2015103602 |
| Title |
Pd1 and Pdl1 Antibodies and Vaccine Combinations and Use of Same for Immunotherapy. |
| Abstract |
Disclosed herein is a vaccine comprising an antigen and PD1 antibody and/or PDL1 antibody. Also disclosed herein is a method for enhancing an immune response in a subject. The method may comprise administering the vaccine to the subject in need thereof. |
| Applicant(s) |
The Trustes of the University of Pennsylvania |
| Patent ID |
WO2015095423 |
| Title |
Combination Therapy Comprising Ox40 Binding Agonists and Pd-1 Axis Binding Antagonists. |
| Abstract |
The invention provides compositions and methods for treating cancers. The method comprises administering a PD-1 axis binding antagonist and an OX40 binding agonist. |
| Applicant(s) |
Genentech, Inc |
| Patent ID |
WO2015095410 |
| Title |
Methods of Treating Cancer Using Pd-1 Axis Binding Antagonists and An Anti-Cd20 Antibody. |
| Abstract |
The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an anti-CD20 antibody and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer. |
| Applicant(s) |
Genentech, Inc |
| Patent ID |
WO2015095404 |
| Title |
Methods of Treating Cancers Using Pd-1 Axis Binding Antagonists and Taxanes. |
| Abstract |
The invention provides methods and compositions for treating cancer and for enhancing immune function in an individual having cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane. |
| Applicant(s) |
Genentech, Inc |
| Patent ID |
WO2015088847 |
| Title |
Treating Cancer with A Combination of A Pd-1 Antagonist and A Vegfr Inhibitor. |
| Abstract |
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1. |
| Applicant(s) |
Glaxosmithkline Llc |
| Patent ID |
WO2015058573 |
| Title |
Monoclonal Antibody for Antagonizing and Inhibiting Binding of Programmed Death (Pd-1) To Ligand Thereof and Coding Sequence and Use Thereof. |
| Abstract |
Disclosed in the present invention are a mouse monoclonal antibody for antagonizing and inhibiting the binding of a programmed death-1 (PD-1) to the ligand thereof, and the heavy chain variable region. |
| Applicant(s) |
Suzhou Stainwei Biotech Inc |
| Patent ID |
WO2015036394 |
| Title |
Antibodies Against Pd-1 and Uses Thereof. |
| Abstract |
The present invention provides antibodies and antigen-binding fragments that specifically bind PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders. |
| Applicant(s) |
Medimmune Limited |
| Patent ID |
WO2015009856 |
| Title |
Methods of Treating Cancer Using Pd-1 Axis Binding Antagonists and Tigit Inhibitors. |
| Abstract |
The present disclosure describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection. |
| Applicant(s) |
Genentech, Inc |
| Patent ID |
WO2014179664 |
| Title |
Antibodies Directed Against Programmed Death-1 (Pd-1). |
| Abstract |
The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a programmed death-1 (PD-1) protein. The invention provides a PD-1-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the PD-1-binding agent to treat a cancer or an infectious disease. |
| Applicant(s) |
Anaptysbio, Inc |
| Patent ID |
WO2013019906 |
| Title |
Methods of Treating Cancer Using Pd-1 Axis Binding Antagonists and Mek Inhibitors. |
| Abstract |
The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer. |
| Applicant(s) |
Genentech, Inc |
| Patent ID |
WO2012145493 |
| Title |
Antibodies and Other Molecules That Bind B7-H1 and Pd-1. |
| Abstract |
The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to B7-H1 or PD-1. In some embodiments such molecules are additionally capable of modulating the ability of B7-H1 or B7-DC to bind to PD-1 or are capable of affecting the signaling activity of the B7-H1 or PD-1. The invention additionally concerns the uses of such molecules in the diagnosis and treatment of cancer and other diseases. |
| Applicant(s) |
Amplimmune, Inc |
| Patent ID |
WO2012135408 |
| Title |
Stable formulations of Antibodies To Human Programmed Death Receptor Pd-1 and Related Treatments. |
| Abstract |
The present invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. The present invention further provides methods for treating various cancers and chronic infections with stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. |
| Applicant(s) |
Merck Sharp & Dohme Corp |
| Patent ID |
WO2011159877 |
| Title |
Bi-Specific Antibodies Against Tim-3 and Pd-1 for Immunotherapy In Chronic Immune Conditions. |
| Abstract |
Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors PD-1 and TIM-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer. |
| Applicant(s) |
The Brigham and Women'S Hospital, Inc |
| Patent ID |
WO2011110604 |
| Title |
Pd-1 Antibody. |
| Abstract |
A humanised agonistic antibody which binds human PD-1 comprising a heavy chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID N0:1 for CDR-H1, the sequence given in SEQ ID NO : 2 for CDR-H2 and the sequence given in SEQ ID NO: 3 for CDR-H3 and the heavy chain framework region is derived from human sub-group sequence VH4 3-1 4-30.4 + JH4 (SEQ ID NO: 33). The disclosure also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules. |
| Applicant(s) |
Ucb Pharma |
| Patent ID |
WO2010089411 |
| Title |
Pd-1 Antibodies and Pd-L1 Antibodies and Uses Thereof. |
| Abstract |
The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof. |
| Applicant(s) |
Inserm (Institut National De La Sante et De La Recherche Medicale) |
| Patent ID |
WO2010036959 |
| Title |
Human Anti-Pd-1, Pd-L1, and Pd-L2 Antibodies and Uses Therefor. |
| Abstract |
The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein. |
| Applicant(s) |
Dana-Farber Cancer Institute, Inc |
| Patent ID |
WO2010029435 |
| Title |
Pd-1 Specific Antibodies and Uses Thereof. |
| Abstract |
One aspect of the present disclosure provides antibodies that can act as agonists of PD-1, thereby modulating immune responses regulated by PD-1. Another aspect of the disclosure provides compositions comprising PD-1 specific antibodies and their use in methods of down regulating the immune response. These methods can be practiced on any subject, including humans or animals. Anti-PD-1 antibodies disclosed herein may be used, in another aspect of the invention to detect PD-1 or its fragments in a biological sample. The amount of PD-I detected may be correlated with the expression level of PD-1, and associated with the activation status of immune cells (e.g., activated T cells, B cells, and/or monocytes) in the subject. |
| Applicant(s) |
Isis Innovation Limited |
| Patent ID |
WO2010029434 |
| Title |
Pd-1 Specific Antibodies and Uses Thereof. |
| Abstract |
One aspect of the present disclosure provides antibodies that can act as agonists of PD-1, thereby modulating immune responses regulated by PD-1. Another aspect of the disclosure provides compositions comprising PD-1 specific antibodies and their use in methods of down regulating the immune response. These methods can be practiced on any subject, including humans or animals. Anti-PD-1 antibodies disclosed herein may be used, in another aspect of the invention to detect PD-1 or its fragments in a biological sample. The amount of PD-1 detected may be correlated with the expression level of PD-1, and associated with the activation status of immune cells (e.g., activated T cells, B cells, and/or monocytes) in the subject. |
| Applicant(s) |
Isis Innovation Limited |
| Patent ID |
WO2010027828 |
| Title |
Pd-1 Antagonists and Methods of Use Thereof. |
| Abstract |
Compositions and methods for enhancing and/or prolonging the activation of T cells (i.e., increasing antigen- specific proliferation of T cells, enhancing cytokine production by T cells, stimulating differentiation ad effector functions of T cells and/or promoting T cell survival) or overcoming T cell exhaustion and/or anergy are provided. Suitable compositions include PD-I receptor antagonists that bind to and block the endogenous PD-I receptor without triggering inhibitory signals from PD-I, or bind to and block PD-I receptor ligands and preventing them from interacting with PD-I receptors. Methods for using the PD-I receptor antagonists to enhance immune responses in subjects in need thereof are provided. |
| Applicant(s) |
Amplimmune, Inc |
| Patent ID |
WO2010027423 |
| Title |
Compositions of Pd-1 Antagonists and Methods of Use. |
| Abstract |
Methods of treating cancer and infectious diseases utilizing a treatment regimen comprising administering a compound that reduces inhibitory signal transduction in T cells, in combination with a potentiating agent, such as cyclophosphamide, to produce potent T cell mediated responses, are described. Compositions comprising the PD-1 antagonists and potentiating agents useful in the methods of the invention are also disclosed. |
| Applicant(s) |
AMPLIMMUNE, INC. LANGERMAN, Solomon LIU, Linda |
